Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Amgen.
Target Audience: The intended audience for this activity is oncologists, oncology pharmacists, and other health care professionals involved in the management of patients with cancer who may benefit from biologic therapy.
Learning Objectives: Upon successful completion of this activity, participants should be able to:
- Explain the differences between biologics and their reference biologic compound in terms of structure, manufacturing, regulation, and/or clinical properties.
- Evaluate the current FDA standards to evaluate and approve biosimilars and implications for providers, payors, and patients.
- Assess the latest evidence regarding available and late-stage biosimilars.
- Assess effective strategies to address common patient concerns regarding the use of biosimilars.
Faculty:
Sanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St. Luke’s Cancer Center
Bethlehem, PA
Professor of Medicine
Temple University
Philadelphia, PA
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Clinical Coordinator of Hematology/Oncology
The University of Arizona Cancer Center
Clinical Assistant Professor
The University of Arizona College of Pharmacy
Phoenix, AZ
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is acceptable for 0.75 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-19-003-H01-P, effective 6/28/2019. This is a knowledge-based activity and there is no fee to attend.
This enduring material is approved for 1 year from the date of original release, June 28, 2019 to June 27, 2020.
How to Participate in This Activity and Obtain CME/CPE Credit:
To participate in this activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate or an ACPE Statement of Credit. Participants claiming CPE credit will be reported directly to CPE Monitor within 30 days of successful completion of the activity.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all CME/CPE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME/CPE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CPE activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty report the following relationships:
Sanjiv S. Agarwala, MD
No relevant financial relationships to disclose.
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Consulting Fee: Amgen, Sandoz
Reviewers report the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME/CPE Questions?
Contact us at cme@vindicoCME.com